ALNYLAM PHARMACEUTICALS, INC. Cash Flow Statement
ALNY / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
ALNYLAM PHARMACEUTICALS, INC. generated $524M in operating cash flow and $465M in free cash flow in FY2025. Free cash flow margin was 12.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$18.3M | -$278.2M | -$440.2M | -$1.1B | -$852.8M | -$858.3M | -$490.9M | -$761.5M | -$490.9M | -$410.1M | -$290.1M | -$360.4M | -$89.2M | -$106.0M | -$57.6M |
| Depreciation & Amortization | - | $55.1M | $51.6M | $39.1M | $36.8M | $30.2M | $11.9M | $12.8M | $11.9M | $9.6M | $19.1M | $11.9M | $10.2M | $9.0M | $5.1M |
| Operating Cash Flow | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M | -$615.0M | -$382.8M | -$562.6M | -$382.8M | -$307.7M | -$189.1M | -$165.6M | -$68.7M | -$115.6M | -$87.1M |
| Capital Expenditures | $58.7M | $34.3M | $62.2M | $72.1M | $76.4M | $70.4M | $104.2M | $126.9M | $104.2M | $64.6M | $12.9M | $9.0M | $4.0M | $8.3M | $1.3M |
| Free Cash Flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M | -$685.3M | -$487.0M | -$689.5M | -$487.0M | -$372.3M | -$202.1M | -$174.6M | -$72.7M | -$124.0M | -$88.4M |
| FCF Margin | 12.5% | -1.9% | 2.3% | -59.1% | -85.0% | -139.1% | -541.6% | -920.5% | - | - | - | - | - | - | - |